Simple Summary HER2-positive breast cancer (BC), which accounts for~ 20% of BC, is one
of the more aggressive and has the worst overall survival rate among them. These patients …

Antibody-drug conjugates (ADCs) are a promising class of cancer biopharmaceuticals that
exploit the specificity of a monoclonal antibody (mAb) to selectively deliver highly cytotoxic …

Novel antibody-drug conjugates against HER2 are showing high activity in HER2-negative
breast cancer (BC) with low HER2 expression (ie, 1+ or 2+ and lack of ERBB2 amplification) …

Antibody‐drug conjugates (ADCs) are a rapidly developing therapeutic approach in cancer
treatment that has shown remarkable activity in breast cancer. Currently, there are two ADCs …

Simple Summary A proportion of breast tumors bear the oncogenic transmembrane tyrosine
kinase protein HER2. Even though therapies that target HER2 have changed the prognosis …

Dolastatin 10 is an extremely potent broad-spectrum antitubulin anticancer pentapeptide
isolated from Dolabella auricularia. The two-dimensional structure was elucidated by NMR …

Introduction Breast cancer (BC) is the most common cancer in women and, despite the
undeniable improvements in the outcome of these patients obtained in the last decade, the …

Cancer has always been a threat to human health with its high morbidity and mortality rates.
Traditional therapy, including surgery, chemotherapy and radiotherapy, plays a key role in …

PF-06804103 is an anti-HER2 antibody–drug conjugate with auristatin payload. We
evaluated its safety, tolerability, and antitumor activity in patients with advanced …

Antibody–drug conjugates (ADCs) constitute a relatively new group of anticancer agents,
whose first appearance took place about two decades ago, but a renewed interest occurred …